Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11430886 | 0.79 | TP53 (0.41) | TP53TDP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8820544 | 0.75 | TSHR (0.39) | TP53TDP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2079486 | 0.75 | TSHR (0.39) | TP53TDP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1749816 | 0.74 | TP53 (0.37) | TP53TDP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11872271 | 0.74 | TSHR (0.34) | TP53TDP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7490235 | 0.73 | TSHR (0.37) | TP53TDP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14105288 | 0.72 | TSHR (0.40) | TP53TDP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL905270 | 0.72 | TSHR (0.36) | TP53TDP1TSHRSMN1; SMN2PPARD | |
| SCHEMBL6553791 | 0.72 | TSHR (0.36) | TP53TDP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4283889 | 0.72 | TP53 (0.34) | TP53TDP1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159961-A1 | BIOSYNTHESIS OF CHEMICALLY DIVERSIFIED NON-NATURAL TERPENE PRODUCTS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-05-25 | — | — | US | disclosed |
| US-7649093-B2 | (2E)-3-[4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-(trifluoromethyl)phenyl]-2-propenoic acid; menopausal or postmenopausal disorders, vasomotor symptoms, vaginal atrophy, atrophic vaginitis, endometriosis, female sexual dysfunction, breast cancer, depression, diabetes, osteoporosis | Glaxo Smith Kline LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070276000-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-11-29 | — | — | US | disclosed |
| EP-1150980-B1 | 16-HALOGEN-EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| EP-1773750-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006002185-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050187270-A1 | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-25 | — | — | US | disclosed |
| US-6930102-B2 | 16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use | SCHERING AG (DE) | 2005-08-16 | — | — | US | disclosed |
| US-20040058969-A1 | Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use | SCHERING AG (DE) | 2004-03-25 | — | — | US | disclosed |
| US-20040014978-A1 | 16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use | SCHERING AG (DE) | 2004-01-22 | — | — | US | disclosed |
| US-6610736-B1 | Antitumor | SCHERING AG (DE) | 2003-08-26 | — | — | US | disclosed |
| EP-1150980-A2 | 16-HALOGEN-EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000049021-A2 | 16-HALOGEN-EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-24 | — | — | WO | disclosed |
| EP-0912511-A1 | 5-INDOLYL-2,4-PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | Smithkline Beecham S.p.A. (IT) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001423-A1 | 5-INDOLYL-2,4-PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159961-A1 | BIOSYNTHESIS OF CHEMICALLY DIVERSIFIED NON-NATURAL TERPENE PRODUCTS | GGPS1, DHPS, FDPS | TP53 2052/4885TDP1 2584/4885CYP3A4 19/4885 |
| US-20040014978-A1 | 16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use | EPOR, CYP2F1, REV1 | TP53 4227/4885TDP1 3990/4885CYP3A4 91/4885 |
| US-20050187270-A1 | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use | ABCB1, UGT2B17, CYP7B1 | TP53 3641/4885TDP1 4490/4885CYP3A4 50/4885 |
| US-20070276000-A1 | CHEMICAL COMPOUNDS | GPER1, ESR2, ESR1 | TP53 1759/4885TDP1 4261/4885CYP3A4 318/4885 |
| US-20040058969-A1 | Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use | TUBA1C, TUBB1, MALT1 | TP53 826/4885TDP1 2607/4885CYP3A4 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.